Opinion

Video

Clinical Impact of Subcutaneous Antibody-Drug Conjugates in HER2+ Breast Cancer

Author(s):

Joyce O’Shaughnessy, MDMelinda L. Telli, MD

Breast cancer specialists outline their institutions’ practices regarding the choice between subcutaneous and intravenous antibody-drug conjugates in patients with HER2+ breast cancer.

Video content above is prompted by the following question(s):

  • What is your institution’s approach to intravenous PH vs. subcutaneous PH in the neoadjuvant setting?
Related Videos
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"
Video 2 - 2 KOLs are featured in, "Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway"
4 KOLs are featured in this series
4 KOLs are featured in this series
Paolo Tarantino, MD
Andrew Davis, MD
4 KOLs are featured in this series
4 KOLs are featured in this series
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Related Content
Vivek Subbiah, MD, of Sarah Cannon Research Institute
July 2nd 2024

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup
June 27th 2024

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.
June 28th 2024

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Peter Forsyth, MD
June 26th 2024

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

Zefei Jiang, MD
June 25th 2024

First-Line Toripalimab Plus Chemo Wins Approval in China for Advanced TNBC